London, June 12th 2017 – the Social Stock Exchange – society’s market for impact investing – has today announced that regenerative medicine company Videregen Limited (www.videregen.com) has been approved as a member following the ratification of its impact report by the independent Admissions Panel.
Videregen is a clinical stage regenerative medicine company using a proprietary stem cell based technology platform to develop a range of personalised organ replacement products for orphan (low incidence) indications.
The Social Stock Exchange enables its accredited impact issuers to increase their visibility, raise capital and undertake primary or secondary listings of debt or equity instruments.
About the Social Stock Exchange
The Social Stock Exchange provides access to the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities. The aim of the exchange is to help these businesses connect with investors and unlock capital at scale. All issuer member companies must meet a rigorous set of criteria before joining, including the publication of an Impact Report.
The Social Stock Exchange has an agreement with NEX Exchange (formerly ISDX) to operate the Social Stock Exchange branded market segment for impact businesses.
The Social Stock Exchange Ltd (FRN: 625231) is an appointed representative of Kession Capital Limited (FRN: 582160) which is authorised and regulated by the Financial Conduct Authority (“FCA”) in the UK.
NEX is a Recognised Investment Exchange operating a regulated market and a growth market and provides a secondary market trading facility. NEX is supervised by the FCA.
For more information please contact:
T: +44 (0) 7590 805 003
T: +44 7973 284 749
Social Stock Exchange
T: +44 (0) 203 608 8056
Steve Bloor, CEO
T: +44 (0) 151 482 9350
Emma Palmer Foster
Strategic Communications Consultant
T: +44 (0) 7880 787185